Skip to content

Study · Non-randomized trial · n = 25 · 1994

4 results

Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.

Nielsen NM, von der Recke P, Hansen MA, Overgaard K, Christiansen C

Calcified tissue international1 Jul 1994Cited by 24 (Europe PMC)

PMID7922794 (opens in a new tab)DOI10.1007/bf00310161 (opens in a new tab)PepBankPUB-07922794
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with established osteoporosis, rectal salmon calcitonin reduced serum and urine turnover markers by 15-40% after control correction (P < 0.05-0.01).

    In plain wordsIn women with osteoporosis, rectal calcitonin reduced bone turnover markers compared with untreated controls.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBone turnover markers with rectal treatment
    Study

    n = 25

    Comparator
    Untreated age-matched women
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU daily · rectal · 1 yearAs given in this study (human).

    Measurements

    Control-corrected decrease in serum and urine bone turnover markers
    15 to 40%
    rectal sCT 100 IU daily; range reported for both administration forms

    Source sentences

    Summary
    Both administration forms revealed significant control group-corrected decreases in serum and urine markers of bone turnover of 15-40% (P < 0.05-0.01) and positive outcomes of 2% in alpha BMCarm (P < 0.01).
    2 context sentences
    Summary · context
    We reviewed data on 42 postmenopausal women with established osteoporosis (forearm fracture or a low bone mass) who had been randomly treated for 1 year with either rectal salmon calcitonin (sCT), 100 IU daily (n = 25) or nasal sCT, 200 IU daily (n = 17) applying an estimation algorithm for bone loss rates.
    Summary · context
    A group of 18 age-matched women who received no treatment served as controls.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rectal calcitonin produced a control-corrected positive outcome of 2% in alpha BMCarm (P < 0.01).

    In plain wordsIn women with osteoporosis, rectal calcitonin improved forearm bone mineral content change compared with controls.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseDistal forearm bone mineral content change with rectal treatment
    Study

    n = 25

    Comparator
    Untreated age-matched women
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU daily · rectal · 1 yearAs given in this study (human).

    Measurements

    Control-corrected alpha BMCarm outcome
    2%
    rectal sCT 100 IU daily; value reported for both administration forms

    Source sentences

    Summary
    Both administration forms revealed significant control group-corrected decreases in serum and urine markers of bone turnover of 15-40% (P < 0.05-0.01) and positive outcomes of 2% in alpha BMCarm (P < 0.01).
    2 context sentences
    Summary · context
    We reviewed data on 42 postmenopausal women with established osteoporosis (forearm fracture or a low bone mass) who had been randomly treated for 1 year with either rectal salmon calcitonin (sCT), 100 IU daily (n = 25) or nasal sCT, 200 IU daily (n = 17) applying an estimation algorithm for bone loss rates.
    Summary · context
    A group of 18 age-matched women who received no treatment served as controls.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with established osteoporosis, nasal salmon calcitonin reduced serum and urine turnover markers by 15-40% after control correction (P < 0.05-0.01).

    In plain wordsIn women with osteoporosis, nasal calcitonin reduced bone turnover markers compared with untreated controls.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBone turnover markers with nasal treatment
    Study

    n = 17

    Comparator
    Untreated age-matched women
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · 1 yearAs given in this study (human).

    Measurements

    Control-corrected decrease in serum and urine bone turnover markers
    15 to 40%
    nasal sCT 200 IU daily; range reported for both administration forms

    Source sentences

    Summary
    Both administration forms revealed significant control group-corrected decreases in serum and urine markers of bone turnover of 15-40% (P < 0.05-0.01) and positive outcomes of 2% in alpha BMCarm (P < 0.01).
    2 context sentences
    Summary · context
    We reviewed data on 42 postmenopausal women with established osteoporosis (forearm fracture or a low bone mass) who had been randomly treated for 1 year with either rectal salmon calcitonin (sCT), 100 IU daily (n = 25) or nasal sCT, 200 IU daily (n = 17) applying an estimation algorithm for bone loss rates.
    Summary · context
    A group of 18 age-matched women who received no treatment served as controls.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, nasal calcitonin produced a control-corrected positive outcome of 2% in alpha BMCarm (P < 0.01).

    In plain wordsIn women with osteoporosis, nasal calcitonin improved forearm bone mineral content change compared with controls.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseDistal forearm bone mineral content change with nasal treatment
    Study

    n = 17

    Comparator
    Untreated age-matched women
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU daily · intranasal · 1 yearAs given in this study (human).

    Measurements

    Control-corrected alpha BMCarm outcome
    2%
    nasal sCT 200 IU daily; value reported for both administration forms

    Source sentences

    Summary
    Both administration forms revealed significant control group-corrected decreases in serum and urine markers of bone turnover of 15-40% (P < 0.05-0.01) and positive outcomes of 2% in alpha BMCarm (P < 0.01).
    2 context sentences
    Summary · context
    We reviewed data on 42 postmenopausal women with established osteoporosis (forearm fracture or a low bone mass) who had been randomly treated for 1 year with either rectal salmon calcitonin (sCT), 100 IU daily (n = 25) or nasal sCT, 200 IU daily (n = 17) applying an estimation algorithm for bone loss rates.
    Summary · context
    A group of 18 age-matched women who received no treatment served as controls.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.